Clinical management of advanced gastric cancer: the role of new molecular drugs. - Wikidata - awgldk - TriplyDB

Clinical management of advanced gastric cancer: the role of new molecular drugs.

Clinical management of advanced gastric cancer: the role of new molecular drugs.

http://www.wikidata.org/entity/Q38263841

about

HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice Targeted therapy for advanced gastric cancer: A review of current status and future prospects Gastric Cancer: New Drugs - New Strategies Gastric cancer: current and evolving treatment landscape The role of antiangiogenic agents in the treatment of gastric cancer: A systematic review and meta-analysis CCAAT/enhancer-binding protein α decreases the viability of gastric cancer cells Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer.Efficient isolation and proteomic analysis of cell plasma membrane proteins in gastric cancer reveal a novel differentiation and progression related cell surface marker, R-cadherin.Introducing biomarker panel in esophageal, gastric, and colon cancers; a proteomic approach.Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.Ramucirumab: A Review in Advanced Gastric Cancer.Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives.Current advances in targeted therapies for metastatic gastric cancer: improving patient care.NF-κB Signaling in Gastric Cancer.Epidermal growth factor receptor expression and gene copy number analysis in gastric carcinoma samples from Chinese patients Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study.MicroRNA-34a regulates proliferation and apoptosis of gastric cancer cells by targeting silent information regulator 1.Artemisia Capillaris leaves inhibit cell proliferation and induce apoptosis in hepatocellular carcinoma.Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil.Knockdown of CCNO decreases the tumorigenicity of gastric cancer by inducing apoptosis

P2860

Q26741253-DB57F155-F8E3-4B12-A3C8-2872402387A1 Q26774138-86B61A0F-D294-44BE-B5B8-272B5EB45A60 Q27028079-208FE1F9-FFE5-49BA-8EA5-73DF3CAAED57 Q28073757-74ABB727-775C-4E14-BD0F-8F7038EA19C6 Q30235387-9198113D-900D-4DE9-AD7B-FBBE87B0F178 Q33751341-FBDDA3D4-34AB-4E6E-987F-47506457EBD1 Q36155142-A7176757-8095-408F-8708-38771FFBAE4C Q37366255-71E5033C-C196-4FD1-B27D-DB3F6CF8B5AF Q38316610-5F0E1EA5-981B-4242-807B-E5AA27FAB64A Q38578404-D1028377-AD5D-4654-AED5-C49E926FF978 Q38581171-A8BF72F0-F5AA-41C8-B8D9-2665008878CF Q38632917-33528190-7C29-4A85-8357-574C1F7B0C9F Q38720829-92913461-7EB7-4789-B4BB-EC7C9263A9FF Q39204794-08B5D6A4-9790-44AB-9481-76EC36ADBC03 Q42052616-4559D8F9-158F-42F1-8DBB-E0F8E34CAA17 Q42378852-25F231C5-8BF9-42BA-956C-5E3F9ABBF446 Q52629304-61F67726-DD1B-4F7F-8146-75F9DDEB2E1E Q54959451-16FCE788-6287-488C-B651-D66EA1D0654E Q55057845-81ED1522-94D8-4784-AF40-0E39D315F264 Q59126223-E88AFED3-1954-4B37-9407-878879B1B4C7

P2860

Clinical management of advanced gastric cancer: the role of new molecular drugs.

http://www.wikidata.org/entity/Q38263841

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Clinical management of advanced gastric cancer: the role of new molecular drugs.

@en

type

label

Clinical management of advanced gastric cancer: the role of new molecular drugs.

@en

prefLabel

Clinical management of advanced gastric cancer: the role of new molecular drugs.

@en

P1433

Q38263841-AC95950D-0830-4706-A844-D678B22C2053

P1476

Q38263841-805649D7-C908-400D-974C-D601625FDEF0

P2093

Q38263841-3160ECD0-B877-44BC-9C20-4EA789A6D87D

Q38263841-38009208-2597-48FF-A6B1-23FA8FFD9315

Q38263841-80794DA6-B187-4639-B6DF-243D7A41B072

Q38263841-8C39AFAC-45A8-45DB-8E34-D52CAFBE54D8

Q38263841-917EA509-46B6-482E-8EED-61E236393509

Q38263841-9CBFB2A2-60F0-4FB0-8CE5-46DD42F0B8D0

Q38263841-C6275C2B-8AFE-4F5F-B039-DB51F240F593

P2860

Q38263841-016BFF19-8B06-4182-BCA5-2B88C4FF6B51

Q38263841-01D33308-F13A-4DC0-A617-343CE8D0914F

Q38263841-0782C051-EAB8-4950-A62A-F9EA98DB97FD

Q38263841-09C52050-5B12-401C-BFA8-5A80F7D89AEA

Q38263841-0D080D64-8C72-4311-944D-966BB236DF67

Q38263841-0D732580-2641-4E27-9185-A28E6CA27592

Q38263841-0F10E25B-DF14-4CA3-BBFF-893F58BB3B7F

Q38263841-0F7EAC77-724A-47FA-9F7A-4D5FE25DC3C9

Q38263841-1292349C-C584-4715-9A0E-91331B5929E7

Q38263841-1B266F0B-C561-45B1-A961-A66F63E655B6

P304

Q38263841-A957F0BE-84A7-494E-9DC5-47C15081D48F

P31

Q38263841-42DD710F-40F4-4608-9F71-7939B8189907

P356

Q38263841-EDB81076-5805-4C64-9951-023396BA37FB

P407

Q38263841-5A7A47D7-4817-4892-8F22-B72033CDF2AC

P433

Q38263841-53E44BAE-5A33-4C45-BFEF-E9FEBE2E43D0

P478

Q38263841-891DFE52-8A93-4642-8D67-D8AFA2E17459

P50

Q38263841-0E21C1DA-3BB7-4352-8484-E907DF542C74

Q38263841-11CDDF34-F191-403E-826A-746134514EEF

Q38263841-3337341C-C6D0-4D8A-AE43-85C770001786

Q38263841-746BF063-3038-4123-8C99-3C5ACAA0E35F

Q38263841-78D9013B-EC84-4016-A64A-8CEEA64E8C96

Q38263841-BA929E0A-A962-4356-8538-0BDAADAE7B72

Q38263841-C65CEE3D-1AE2-4AEF-A729-70D815248A21

Q38263841-F9974860-E8F2-4365-B8F3-9F8AE255F616

P577

Q38263841-2D7AD75C-290A-4E76-98F9-5687ED41740F

P5875

Q38263841-BBB9CD70-124F-44D1-92F7-B13A77B9F513

P698

Q38263841-43BADE42-602E-41C9-90B7-F3A3078A0E44

P932

Q38263841-D81EA9D8-209A-4513-AAC4-C1BD39D2A56A

P356

WJG.V20.I40.14537

P1433

World Journal of Gastroenterology

P1476

Clinical management of advanced gastric cancer: the role of new molecular drugs

@en

P2093

Annamaria Auricchio

http://www.w3.org/2001/XMLSchema#string

Beatrice Savastano

http://www.w3.org/2001/XMLSchema#string

Ferdinando De Vita

http://www.w3.org/2001/XMLSchema#string

Jole Ventriglia

http://www.w3.org/2001/XMLSchema#string

Maria Maddalena Laterza

http://www.w3.org/2001/XMLSchema#string

Natale Di Martino

http://www.w3.org/2001/XMLSchema#string

Valentina Gambardella

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Chemotherapy for advanced gastric cancer

Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models

Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer

A comprehensive pathway map of epidermal growth factor receptor signaling

Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family

Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

The biology of VEGF and its receptors

P304

14537-14558

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V20.I40.14537

http://www.w3.org/2001/XMLSchema#string

P407

P433

40

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Fortunato Ciardiello

Vincenzo Sforza

Gennaro Galizia

Michele Orditura

Angelica Petrillo

P577

2014-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

267865351

http://www.w3.org/2001/XMLSchema#string

P698

25356019

http://www.w3.org/2001/XMLSchema#string

P932

4209522

http://www.w3.org/2001/XMLSchema#string